Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

cersurvey-15

The National Pharmaceutical Council’s (NPC) fifth annual survey, "Comparative Effectiveness Research (CER) and the Environment for Health Care Decision-Making," provides a snapshot of stakeholders’ perceptions of the key players in the main aspects of the CER process, from setting priorities to translating and disseminating the research findings.

Among the findings:

  • CER’s importance in the health care landscape was clearly recognized by stakeholders, with 92% of respondents saying it is “very important” or “somewhat important,” which is consistent with their responses in previous years. Although these respondents view CER as important, its impact has not yet been felt. “Moderate” or “substantial improvement” in health care decision-making because of CER won’t likely be felt for another three (83%) to five years (93%).
  • The Patient-Centered Outcomes Resource Institute (PCORI) (75%), the National Institutes of Health (NIH) (63%) and the Agency for Healthcare Research and Quality (AHRQ) (62%), respectively, are viewed as leaders in setting the research priorities that will be addressed by CER.
  • When it comes to playing key roles in establishing research standards, PCORI is seen still on top at 77%, possibly because it requires its grant recipients to follow the research standards set out in its methodology report. AHRQ (68%) was next, followed by NIH and academia, both at 50%.
  • PCORI also was recognized by respondents as the key organization in funding and monitoring research (81%), followed by NIH (73%) and the biopharmaceutical industry (65%), which makes large investments in research.
  • Expectations for leadership in conducting research are strongest for academia (86%), the biopharmaceutical industry (60%) and NIH (48%).
  • In assessing which stakeholders are expected to play the greatest role in the translation and dissemination of research, AHRQ (78%), PCORI (69%) and academia (60%) are perceived as the lead players. AHRQ is also tasked by federal law to disseminate PCORI’s work. 

The survey also asked respondents about the health care decision-making environment, considering factors that could impact the quality of CER and its usefulness in making treatment and coverage decisions:

  • Stakeholders remain optimistic that there is growing movement toward widely agreed-upon research standards, which would provide more consistency in the conduct and evaluation of CER. In the survey, 49% of respondents acknowledged this trend, a statistically significant difference from 24% in 2011.
  • Despite the growing focus on patient-centered care, only 41% of stakeholders felt that research priorities adequately addressed the treatment choices faced by patients and providers.
  • Less than half of respondents said that there is no or little transparency in the processes used by decision-makers to interpret evidence.
  • Fifty-eight percent of respondents said that the value of treatments remains narrowly focused on only clinical effectiveness, rather than taking into account factors that matter to patients, such as quality of life, workplace productivity, adherence to treatments and other outcomes.
  • Sixty-seven percent said that the evidence base is not complete enough to inform the choices faced by patients and providers.
  • Forty-four percent felt that the use of real-world evidence in making health care decisions is still limited.
  • When it comes to accounting for variability in patient responses, 43% of respondents felt that individual treatment effects are not taken into consideration.

Survey Parameters:

The survey, conducted by Scientific & Social Systems on behalf of NPC, was fielded between September 23, 2014, and January 16, 2015, among key stakeholders who are knowledgeable about CER. These stakeholders included researchers/thought leaders; government; insurers/health plans; employers; business coalitions; and associations. A total of 122 stakeholders participated.

Related Resources:

Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Newsletter Volume

E.V.I.dently: April 2016

MessageValue Assessment Through a Broader, Patient-Focused LensNPC has developed “Guiding Practices for Patient-Centered Value Assessment” to help...
Commentary and Testimony Page

NPC Comments on Revised PCORI Methodology Standards

March 28, 2016Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036 Dr. Robin...
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
Press Release

NPC Stakeholder Survey: Impact of Comparative Effectiveness Research On Health Care Decision-Making Still Three to Five Years in the Future

(Washington, DC, March 14, 2016)—The National Pharmaceutical Council (NPC) today released the results of its annual survey of stakeholder views on...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Commentary and Testimony Page

NPC Comments on Revised PCORI Methodology Standards

March 28, 2016Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036 Dr. Robin...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

CER and the Environment for Health Care Decision-Making

The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is continuing to shed light on the current environment...
Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Blog Post

New Study Puts Previous 5 Years of NPC Annual CER Survey Into Perspective

For the last five years, we’ve had our fingers on the pulse of what health care stakeholders are thinking about comparative effectiveness research...
Blog Post

Key Considerations for Cost Effectiveness Thresholds

While putting a price tag on the value of health care services and the life years gained is common in countries including the United Kingdom, Canada...
Blog Post

CER Tweets of the Week: JCER Editorial on Treatment Sequences in Oncology; JNCCN Discusses CER Database Analyses (December 14-18, 2015)

What were comparative effectiveness research (CER) stakeholders talking about on Twitter this week? Popular topics included the Journal of...
cersurvey16

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the...

Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue

A study published in the September 2015 issue of The American Journal of Managed Care introduces a...
  •  
  • 1 of 12
  • >